Lord Lab

Introduction

Inflammatory Bowel Disease (IBD), consisting of Crohn’s disease and ulcerative colitis (UC), happens when the immune system lining the intestines becomes intolerant of the foreign material, most likely the bacteria, that passes through and normally fills the bowels. The Lord lab is investigating how this loss of “tolerance” happens in IBD, to learn how the immune system normally coexists peacefully in close proximity to gut contents.

While still incurable and debilitating, IBD has become much more manageable for some patients in recent years largely due to new and highly specific medications that can often stop immune cells from inflaming the intestines. By carefully examining how such medications specifically affect immune cells in the blood and intestinal biopsies of IBD patients, and correlating these changes with therapeutic success, we provide a better understanding of how IBD happens and, more importantly, how we may ultimately fix it.

Along the way, we are identifying differences in the immune systems of different IBD patients that may explain or predict disease behavior, and serve as “biomarkers” to guide a more personalized approach to treatment.

James Lord
Research Associate Member

James Lord, MD, PhD

Research Associate Member; Principal Investigator, Lord Lab
View Full Bio

Lab Members

Duncan Hindmarch

Duncan Hindmarch

Research Technician, Lord Lab
Ramya Kongla

Ramya Kongala

Research Technician, Lord Lab
Donna Shows

Donna Shows

Research Technician, Lord Lab

Research Projects

Lord Lab Research Project Prev - Effect of Vedolizumab

Effect of Vedolizumab on Immune Cells

We are investigating how the anti-α4β7 drug vedolizumab affects blood and intestinal immune cells.
View Project
Lord Lab Research Project Prev - Cells in IBD

T Cells in Inflammatory Bowel Disease

Correlating T Cell Phenotypes with Pathogenesis in Inflammatory Bowel Disease
View Project

Related Stories

Blog Main Image - 2D Abstract Telemedicine Online Healthcare
September 14, 2022

Clues into Crohn's: Exploring Why the Immune System Attacks Beneficial Bacteria

Your gut is home to a huge community of bacteria called the microbiome. Some bacteria are good, some are bad — and some might hold the key to understanding an inflammatory bowel disease (IBD) like Crohn’s disease and ulcerative colitis.

Read Article
Blog Main Image - Researcher Woman Examining Samples Blue
April 5, 2022

Inside BRI’s Gut Immunity Program

To most people, the gut is just a part of your body that helps digest food.

Read Article
Blog Main Image - Patient Child IV Hospital Bed
December 30, 2021

Could medicines for inflammatory bowel disease help fight type 1 diabetes?

Among the many mysteries of autoimmune diseases, we know one thing for sure: These diseases are connected. They often occur when immune cells called T cells mistakenly attack healthy tissue — say the pancreas in type 1 diabetes (T1D) or the gut in inflammatory bowel disease (IBD).

Read Article

News

News icon

Benaroya Research Institute Awarded $11.4 M NIH U19 Grant to Profile Respiratory Viral Infections in Vulnerable Populations and $3.9M NIH R01 Grant to Develop New Treatments for Type 1 Diabetes

Read More
Science in Seattle Logo

Publication of the Week: PGD2 and CRTH2 counteract Type 2 cytokine–elicited intestinal epithelial responses during helminth infection

Read publication ➡
Science in Seattle Logo

Science in Seattle: Benaroya Research Institute Launches Gut Research Program

Read news ➡